keyword
MENU ▼
Read by QxMD icon Read
search

Zoledronic acid

keyword
https://www.readbyqxmd.com/read/29341831/role-of-bone-modifying-agents-in-multiple-myeloma-american-society-of-clinical-oncology-clinical-practice-guideline-update
#1
Kenneth Anderson, Nofisat Ismaila, Patrick J Flynn, Susan Halabi, Sundar Jagannath, Mohammed S Ogaily, Jim Omel, Noopur Raje, G David Roodman, Gary C Yee, Robert A Kyle
Purpose To update guideline recommendations on the role of bone-modifying agents in multiple myeloma. Methods An update panel conducted a targeted systematic literature review by searching PubMed and the Cochrane Library for randomized controlled trials, systematic reviews, meta-analyses, clinical practice guidelines, and observational studies. Results Thirty-five relevant studies were identified, and updated evidence supports the current recommendations. Recommendations For patients with active symptomatic multiple myeloma that requires systemic therapy with or without evidence of lytic destruction of bone or compression fracture of the spine from osteopenia on plain radiograph(s) or other imaging studies, intravenous administration of pamidronate 90 mg over at least 2 hours or zoledronic acid 4 mg over at least 15 minutes every 3 to 4 weeks is recommended...
January 17, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29329716/gelatin-hydroxyapatite-calcium-sulphate-based-biomaterial-for-long-term-sustained-delivery-of-bone-morphogenic-protein-2-and-zoledronic-acid-for-increased-bone-formation-in-vitro-and-in-vivo-carrier-properties
#2
Deepak Bushan Raina, David Larsson, Filip Mrkonjic, Hanna Isaksson, Ashok Kumar, Lars Lidgren, Magnus Tägil
In this study, a novel macroporous composite biomaterial consisting of gelatin-hydroxyapatite-calcium sulphate for delivery of bone morphogenic protein-2 (rhBMP-2) and zoledronic acid (ZA) has been developed. The biomaterial scaffold has a porous structure and functionalization of the scaffold with rhBMP-2 induces osteogenic differentiation of MC3T3-e1 cells seen by a significant increase in biochemical and genetic markers of osteoblastic differentiation. In-vivo muscle pouch experiments showed higher mineralization using scaffold+rhBMP-2 when compared to an approved absorbable collagen sponge (ACS)+rhBMP-2 as verified by micro-CT...
January 10, 2018: Journal of Controlled Release: Official Journal of the Controlled Release Society
https://www.readbyqxmd.com/read/29316026/treatment-dynamics-of-bone-targeting-agents-among-men-with-bone-metastases-from-prostate-cancer-in-the-united-states
#3
Anne M Butler, Karynsa Cetin, Rohini K Hernandez, B Diane Reams, Robert A Overman, Jung I Kim, Bradford R Hirsch, Amy P Abernethy, Alexander Liede, M Alan Brookhart
PURPOSE: To examine the dynamics of treatment with 2 bone-targeting agents (BTAs)-denosumab and zoledronic acid-among men with bone metastases from prostate cancer. METHODS: Using electronic health record data from oncology practices across the US, we identified prostate cancer patients diagnosed with bone metastasis in 2012/2013 without evidence of BTA use within 6 months prior to diagnosis. We examined the risk and predictors of BTA initiation, interruption, and re-initiation...
January 7, 2018: Pharmacoepidemiology and Drug Safety
https://www.readbyqxmd.com/read/29310035/combined-effects-of-neoadjuvant-letrozole-and-zoledronic-acid-on-%C3%AE-%C3%AE-t-cells-in-postmenopausal-women-with-early-stage-breast-cancer
#4
Tomoharu Sugie, Eiji Suzuki, Akira Yamauchi, Kazuhiko Yamagami, Norikazu Masuda, Naomi Gondo, Eriko Sumi, Takafumi Ikeda, Harue Tada, Ryuji Uozumi, Shotaro Kanao, Yoshimasa Tanaka, Yoko Hamazaki, Nagahiro Minato, Masakazu Toi
INTRODUCTION: Adjuvant bisphosphonates lead to better prognosis in postmenopausal breast cancer. However, the association between clinical outcomes and immune modulation by them is still unclear. METHODS: In this prospective, open-label phase II study, postmenopausal women with estrogen receptor-positive and human epidermal growth factor receptor 2-negative early-stage breast cancer received neoadjuvant letrozole (LET) for one month, followed by treatment with a single dose of zoledronic acid...
January 5, 2018: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/29304080/local-vs-systemic-administration-of-bisphosphonates-in-rat-cleft-bone-graft-a-comparative-study
#5
Christine Hong, Alison Quach, Lawrence Lin, Jeffrey Olson, Taewoo Kwon, Olga Bezouglaia, Jaime Tran, Michael Hoang, Kimberly Bui, Reuben H Kim, Sotirios Tetradis
A majority of patients with orofacial cleft deformity requires cleft repair through a bone graft. However, elevated amount of bone resorption and subsequent bone graft failure remains a significant clinical challenge. Bisphosphonates (BPs), a class of anti-resorptive drugs, may offer great promise in enhancing the clinical success of bone grafting. In this study, we compared the effects of systemic and local delivery of BPs in an intraoral bone graft model in rats. We randomly divided 34 female 20-week-old Fischer F344 Inbred rats into four groups to repair an intraoral critical-sized defect (CSD): (1) Control: CSD without graft (n = 4); (2) Graft/Saline: bone graft with systemic administration of saline 1 week post-operatively (n = 10); (3) Graft/Systemic: bone graft with systemic administration of zoledronic acid 1 week post-operatively (n = 10); and (4) Graft/Local: bone graft pre-treated with zoledronic acid (n = 10)...
2018: PloS One
https://www.readbyqxmd.com/read/29300112/zoledronic-acid-overcomes-chemoresistance-by-sensitizing-cancer-stem-cells-to-apoptosis
#6
H Rouhrazi, N Turgan, G Oktem
Unlike low tumorigenic bulk tumor cells (non-CSCs), cancer stem cells (CSCs) are a subset of tumor cells that can self-renew and differentiate into different cancer subtypes. CSCs are considered responsible for tumor recurrence, distant metastasis, angiogenesis, and drug or radiation resistance. CSCs also are resistant to apoptosis. Zoledronic acid (ZA) is a third generation bisphosphonate that reduces cell proliferation and exhibits anti-tumor effects by inducing cell death in some malignancies; however, the effects of ZA on CSCs are unclear...
January 4, 2018: Biotechnic & Histochemistry: Official Publication of the Biological Stain Commission
https://www.readbyqxmd.com/read/29297602/effect-of-zoledronic-acid-and-denosumab-in-patients-with-low-back-pain-and-modic-change-a-proof-of-principle-trial
#7
Guoqi Cai, Laura L Laslett, Dawn Aitken, Andrew Halliday, Feng Pan, Petr Otahal, Deborah Speden, Tania M Winzenberg, Graeme Jones
The aim of this study was to evaluate the effect of zoledronic acid (ZA) and denosumab on low back pain (LBP) and Modic change (MC) over 6 months. Adults aged ≥40 years with significant LBP for at least 6 months duration and MC (type 1, 2 or mixed) were randomised to receive ZA (5mg/100ml), denosumab (60mg), or placebo. LBP was measured monthly by Visual Analogue Scale (VAS) and the LBP Rating Scale (RS). MC was measured from MRIs of T12-S1 vertebrae at screening and 6 months. 103 participants with moderate/severe LBP (mean VAS=57mm, mean RS=18) and median total MC area 538 mm2 , were enrolled...
January 3, 2018: Journal of Bone and Mineral Research: the Official Journal of the American Society for Bone and Mineral Research
https://www.readbyqxmd.com/read/29289789/zoledronic-acid-increases-the-prevalence-of-medication-related-osteonecrosis-of-the-jaw-in-a-dose-dependent-manner-in-rice-rats-oryzomys-palustris-with-localized-periodontitis
#8
J G Messer, J L Mendieta Calle, J M Jiron, E J Castillo, C Van Poznak, N Bhattacharyya, D B Kimmel, J I Aguirre
OBJECTIVE: Investigate role of dose/duration of zoledronic acid (ZOL), a powerful anti-resorptive (pAR), on prevalence of medication-related osteonecrosis of the jaw (MRONJ) in rice rats (Oryzomys palustris), a species with natural susceptibility to food impaction-induced localized periodontitis (FILP). We hypothesize that ZOL induces MRONJ lesions in rice rats with FILP, and that the prevalence of MRONJ rises with increasing dose and duration of ZOL treatment. METHODS: We performed a toxicology experiment with clinically-relevant doses of ZOL in female rats (N=230) fed standard (STD) rodent chow...
December 28, 2017: Bone
https://www.readbyqxmd.com/read/29288540/expansion-of-human-%C3%AE-%C3%AE-t-cells-for-adoptive-immunotherapy-using-a-bisphosphonate-prodrug
#9
Yoshimasa Tanaka, Kaoru Murata-Hirai, Masashi Iwasaki, Kenji Matsumoto, Kosuke Hayashi, Asuka Kumagai, Mohanad H Nada, Hong Wang, Hirohito Kobayashi, Hiroshi Kamitakahara, Haruki Okamura, Tomoharu Sugie, Nagahiro Minato, Masakazu Toi, Craig T Morita
Cancer immunotherapy with human γδ T cells expressing Vγ2Vδ2 T cell receptor (also termed Vγ9Vδ2) has shown promise because of their ability to recognize and kill most types of tumors in an MHC-unrestricted fashion that is independent of the number of tumor mutations. In clinical trials, adoptive transfer of Vγ2Vδ2 T cells has been shown to be safe and does not require preconditioning. In this report, we describe a method for preparing highly enriched human Vγ2Vδ2 T cells using the bisphosphonate prodrug, tetrakis-pivaloyloxymethyl 2-(thiazole-2-ylamino)ethylidene-1,1-bisphosphonate (PTA)...
December 30, 2017: Cancer Science
https://www.readbyqxmd.com/read/29275525/a-multicenter-case-registry-study-on-medication-related-osteonecrosis-of-the-jaw-in-patients-with-advanced-cancer
#10
Morten Schiodt, Saroj Vadhan-Raj, Mark S Chambers, Ourania Nicolatou-Galitis, Constantinus Politis, Ruxandra Coropciuc, Stefano Fedele, Danielle Jandial, Jeffrey Zhang, Haijun Ma, Deborah P Saunders
PURPOSE: This observational case registry study was designed to describe the natural history of cancer patients with medication-related osteonecrosis of the jaw (ONJ) and evaluate the ONJ resolution rate. METHODS: Adults with a diagnosis of cancer and with a new diagnosis of ONJ were enrolled and evaluated by a dental specialist at baseline and every 3 months for 2 years and then every 6 months for 3 years until death, consent withdrawal, or loss to follow-up...
December 23, 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/29259343/simple-3-4-dihydroxy-l-phenylalanine-surface-modification-enhances-titanium-implant-osseointegration-in-ovariectomized-rats
#11
Ting Ma, Xi-Yuan Ge, Ke-Yi Hao, Bi-Ru Zhang, Xi Jiang, Ye Lin, Yu Zhang
Osteoporosis presents a challenge to the long-term success of osseointegration of endosseous implants. The bio-inspired 3,4-dihydroxy-L-phenylalanine (Dopa) coating is widely used as a basic layer to bind osteogenetic molecules that may improve osseointegration. To date, little attention has focused on application of Dopa alone or binding inhibitors of bone resorption in osteoporosis. Local use of a bisphosphonate such as zoledronic acid (ZA), an inhibitor of osteoclast-mediated bone resorption, has been proven to improve implant osseointegration...
December 19, 2017: Scientific Reports
https://www.readbyqxmd.com/read/29251181/assessment-of-geriatric-predictors-of-adherence-to-zoledronic-acid-treatment-for-osteoporosis-a-prospective-follow-up-study
#12
Ilker Tasci, Umit Cintosun, Umut Safer, M Ilkin Naharci, Ergun Bozoglu, Aydogan Aydogdu, Huseyin Doruk
Objectives Discontinuation of bisphosphonate treatment remains high even with the long acting parenteral options. Whether there are some unidentified causes of noncompliance more specific to aged individuals is unknown. The aim of this study was to investigate baseline predictors of adherence to Zoledronic acid (ZOL) infusions among non-demented older adults with osteoporosis. Methods Patients aged ≥ 65 years who received a first ever ZOL infusion for osteoporosis were prospectively enrolled. Risk factors for osteoporosis and fractures, comorbidities, geriatric assessment measures, including depression, and anticholinergic burden were determined at baseline...
December 18, 2017: Acta Clinica Belgica
https://www.readbyqxmd.com/read/29236901/collagen-sponge-and-rhbmp-2-improve-socket-healing-in-rats-treated-with-zoledronic-acid
#13
Ji-Su Oh, Su-Gwan Kim
The aim of the present study was to evaluate the possible use of a commercial absorbed collagen sponge and bone morphogenetic protein (BMP) for the prevention of bisphosphonate-related osteonecrosis of the jaw (BRONJ) in rats. Twenty rats received intraperitoneal injections of 0.1-mg/kg of zoledronic acid three times a week for eight weeks before the extraction of both maxillary first molars after eight weeks. A collagen sponge (experimental group 1) and a collagen sponge with recombinant human BMP-2 (experimental group 2) were applied to the right extraction sockets of ten rats each...
December 7, 2017: Brazilian Oral Research
https://www.readbyqxmd.com/read/29235095/immune-cells-regulate-vegf-signaling-via-release-of-vegf-and-antagonistic-soluble-vegf-receptor-1
#14
Timm Hoeres, Martin Wilhelm, Manfred Smetak, Elisabeth Holzmann, Gundula Schulze-Tanzil, Josef Birkmann
Vascular endothelial growth factor (VEGF) is an important regulator of physiological and pathological angiogenesis. Beside malignant and stromal cells, local immune cells shape VEGF signaling in the tumor microenvironment. Aminobisphosphonates like zoledronic acid (Zol) are drugs known to inhibit osteoclast activity and bone resorption, but also have immunomodulatory and anti-tumor effects. These properties have previously been linked to the downregulation of VEGF and interference with tumor neo-angiogenesis...
December 13, 2017: Clinical and Experimental Immunology
https://www.readbyqxmd.com/read/29234591/reproductive-hormone-analyses-and-effects-of-adjuvant-zoledronic-acid-in-early-breast-cancer-an-azure-big-01-04-sub-study
#15
Caroline Wilson, Samantha Hinsley, Helen Marshall, David Cameron, Richard Bell, David Dodwell, Robert E Coleman
Purpose: Adjuvant bisphosphonates have been shown to improve disease outcomes in early breast cancer in women who are postmenopausal at the start of treatment. We explored the influence of pretreatment serum levels of reproductive hormones in the hypothalamic-pituitary-gonadal (HPG) axis from a subset of patients included in the AZURE trial to investigate their impact on disease recurrence and whether reproductive hormone measurements are of value in selecting patients for treatment with adjuvant zoledronic acid...
November 2017: Journal of Bone Oncology
https://www.readbyqxmd.com/read/29233701/in%C3%A2-vivo-effects-of-geranylgeraniol-on-the-development-of-bisphosphonate-related-osteonecrosis-of-the-jaws
#16
Filip Koneski, Danica Popovic-Monevska, Icko Gjorgoski, Jovanka Krajoska, Mirjana Popovska, Ilijana Muratovska, Boris Velickovski, Gordana Petrushevska, Vladimir Popovski
BACKGROUND: Bisphosphonate-related osteonecrosis of the jaws (BRONJ) is a complication of the bisphosphonate (BP) treatment and its pathopysiology is still not fully understood. The existing preventive and treatment options require updates and more attention. Geranylgeraniol (GGOH) so far demonstrated an increased activity and viability of the cells previously treated with zoledronic acid (ZA). The aim of this study was to evaluate the in vivo effects of GGOH on the development of BRONJ...
November 20, 2017: Journal of Cranio-maxillo-facial Surgery
https://www.readbyqxmd.com/read/29230158/significant-improvement-of-clinical-symptoms-bone-lesions-and-bone-turnover-after-long-term-zoledronic-acid-treatment-in-patients-with-a-severe-form-of-camurati-engelmann-disease
#17
Giampiero I Baroncelli, Elena Ferretti, Cecilia M Pini, Benedetta Toschi, Rita Consolini, Silvano Bertelloni
Camurati-Engelmann disease (CED) is an ultrarare autosomal dominant bone dysplasia. Cortical thickening of the diaphyses of the long bones with narrowing of the medullary cavity are associated with bone pain, waddling gait, muscular weakness, easy fatigability, and a marfanoid body habitus. There is no specific treatment for CED. Nonsteroidal anti-inflammatory drugs or glucocorticoids are ineffective in improving bone lesions. A family with a mild to severe form of CED is described. Two patients received long-term bisphosphonate treatment: the 19-year-old female proband was treated with zoledronic acid for 2...
November 2017: Molecular Syndromology
https://www.readbyqxmd.com/read/29224174/cost-effectiveness-of-treatments-for-the-management-of-bone-metastases-a-systematic-literature-review
#18
REVIEW
Lazaros Andronis, Ilias Goranitis, Sue Bayliss, Rui Duarte
BACKGROUND: Metastatic cancers occur when cancer cells break away from the primary tumour. One of the most common sites of metastasis is the bone, with several therapeutic options currently available for managing bone metastases. In a resource-constrained environment, policy makers and practitioners need to know which options are cost effective. OBJECTIVE: The aim of this systematic review was to review and appraise published economic evaluations on treatments for the management of bone metastases...
December 9, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/29215680/effects-of-zoledronic-acid-in-experimental-periapical-lesions-in-rats-an-imaging-and-histological-analysis
#19
Talita Ribeiro Tenório de França, Flávia Maria de Moraes Ramos-Perez, Andrea Dos Anjos Pontual, Jurema Freire Lisboa de Castro, Paulo Rogério Ferreti Bonan, Danyel Elias da Cruz Perez
The aim of this study was to assess the imaging and histological features of experimental periapical lesions, including the adjacent alveolar bone, in rats under zoledronic acid treatment. The study used 40 male Wistar rats distributed into 8 groups of 5 animals each: G1: induction of periapical lesion (PL) and weekly intraperitoneal administration (WIPA) of saline solution (0.9% NaCl) for 4 weeks; G2: PL induction and WIPA of zoledronic acid (0.15 mg/kg/week) for 4 weeks; G3: PL induction and WIPA of saline solution for 8 weeks; G4: PL induction and WIPA of zoledronic acid for 8 weeks; G5:WIPA of saline solution for 4 weeks and subsequent PL induction; G6: WIPA of zoledronic acid for 4 weeks and subsequent PL induction; G7: WIPA of saline solution for 8 weeks and subsequent PL induction; G8: WIPA of zoledronic acid for 8 weeks and subsequent PL induction...
September 2017: Brazilian Dental Journal
https://www.readbyqxmd.com/read/29204337/effects-on-bone-resorption-markers-of-continuing-pamidronate-or-switching-to-zoledronic-acid-in-patients-with-high-risk-bone-metastases-from-breast-cancer
#20
J F Hilton, M Clemons, G Pond, H Zhao, S Mazzarello, L Vandermeer, C L Addison
Background: Switching patients who remain at high risk of skeletal related events (SREs) despite pamidronate to the more potent bisphosphonate zoledronate, may be an effective treatment strategy. As part of a previously reported clinic study in this setting, we evaluated whether biomarkers for bone resorption, such as Bone-Specific Alkaline Phosphatase (BSAP), bone sialoprotein (BSP), and N-terminal telopeptide (NTX) correlated with subsequent SRE risk. Methods: Breast cancer patients who remained at high risk of SREs despite at least 3 months of q...
March 2018: Journal of Bone Oncology
keyword
keyword
27337
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"